Assessment and outcome parameters in COPD;Beurteilungs- und Prognosekriterien bei COPD1

Pneumologie

Volumn 63, Issue 1, 2009, Pages 49-55

  Dierkesmann, R ^a   Gillissen, A ^b   Lorenz, J ^c   Magnussen, H ^d   Mitfessel, H ^e   Morr, H ^f   Pfeifer, M ^f   Schultze Werninghaus, G ^g   Steinkamp, G ^h   Teschler, H ⁱ   Voshaar, Th ^j   Welte, T ^k   Worth, H ^k  

^a Klinik Schillerhohe   (Germany)

^b Robert Koch Klinik   (Germany)

^c Klinikum Ludenscheid   (Germany)

^d UNIVERSITY OF LÜBECK   (Germany)

^e Pneumologische Klinik Waldhof Elgershausen ^*

^f UNIVERSITY OF REGENSBURG   (Germany)

^g RUHR UNIVERSITY BOCHUM   (Germany)

^h RUHRLANDKLINIK   (Germany)

ⁱ Medizinische Hochschule Hannover   (Argentina)

^j Klinik III   (Argentina)

^k KLINIKUM FÜRTH   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

STEROID; TIOTROPIUM BROMIDE;

ARTERIAL CARBON DIOXIDE TENSION; BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; DISEASE EXACERBATION; DISEASE SEVERITY; DYSPNEA; EMPHYSEMA; EXERCISE TOLERANCE; FORCED EXPIRATORY VOLUME; FUNCTIONAL RESIDUAL CAPACITY; HUMAN; INSPIRATORY CAPACITY; MORTALITY; OUTCOME ASSESSMENT; OXYGEN TENSION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUALITY OF LIFE; REVIEW; STRUCTURED QUESTIONNAIRE; VITAL CAPACITY; PATHOPHYSIOLOGY; PROGNOSIS; SLEEP DISORDER;

FORCED EXPIRATORY VOLUME; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SLEEP DISORDERS;

EID: 65649132263     PISSN: 09348387     EISSN: 14388790     Source Type: Journal    
DOI: 10.1055/s-0028-1100823     Document Type: Review

References (77)

1. Gross NJ. Outcome measurements in COPD, are we schizophrenic? Chest 2003; 123: 1325-1327
2. Gillissen A, Buhl R, Kardos P et al. Studienendpunkte bei der chronisch? obstruktiven Lungenerkrankung (COPD): "Minimal Clinically Impor? tant Difference". Pneumologie 2008; 62: 149-157
3. Cazzola M, MacNee W, Martinez F?J et al. ATS/ERS Task Force on out? come of COPD. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008; 31: 416-468
4. Franciosi LG, Page CP, Celli BR et al. Marker of disease severity in chro? nic obstructive pulmonary disease. Pulm Pharmacol Ther 2006; 19: 189-199
5. Rabe KF, Hurd S, Anzueto A et al. Global Initiative for Chronic Obstruc? tive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD execu? tive summary. Am J Respir Crit Care Med 2007; 176: 532-555
6. Celli BR, Halbert RJ, Isonaka S et al. Population impact of different defi? nitions of airway obstruction. Eur Respir J 2003; 22: 268-273
7. Calverley PM, Burge PS, Spencer S et al. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax 2003; 58: 659-664
8. Vandevoorde J, Verbanck S, Schuermans D et al. Forced vital capacity and forced expiratory volumen in six seconds as predictors of reduced total lung capacity. Eur Respir J 2008; 31: 391-395
9. Taube C, Holz O, Mücke M et al. Airway response to inhaled hypertonic saline in patients with moderate to severe chronic obstructive pulmo? nary disease. Am J Respir Crit Care Med 2001; 164: 1810-1815
10. Cerveri I, Dore R, Corsico A et al. Assessment of emphysema in COPD: a functional and radiologic study. Chest 2004; 125: 1714-1718
11. 2, maximum work rate, and walking distance in patients with emphysema. Chest 2003; 123: 1394-1400
12. Adams AB, Cakar N, Marini JJ. Static and dynamic pressure?volume curves reflect different aspects of respiratory system mechanics in ex? perimental acute respiratory distress syndrome. Respir Care 2001; 46: 686-693
13. O'Donnell DE, Flüge T, Gerken F et al. Effects of tiotropium on lung hy? perinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004; 23: 832-840
14. 2 tension in chronic obstructive airways disease. Br Med J 1968; 3 (5620): 707-709
15. 2 greater than 60mmHg with and without nocturnal oxyhemoglobin desaturation. Chest 1992; 101: 649-655
16. Oga T, Nishimura K, Tsukino M et al. The effects of oxitropium bromide on exercise performance in patients with stable chronic obstructive pulmonary disease. A comparison of three different exercise tests. Am J Respir Crit Care Med 2000; 161: 1897-1901
17. Oga T, Nishimura K, Tsukino M et al. Analysis of the factors related to mortality in chronic obstructive pulmonary disease: role of exercise capacity and health status. AJRCCM 2003; 167: 544-549
18. Palange P, Antonucci R, Valli G. Exercise testing in the prognostic eva? luation pf patients with lung and heart diseases. In: Ward SA, Palange P (eds). Clinical exercise testing. Eur Respir Mon 2007; 40: 195-207
19. Bernard S, LeBlanc P, Whittom F et al. Peripheral muscle weakness in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 158: 629-634
20. Ottenheijm CA, Heunks LM, Sieck GC et al. Diaphragm dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 172: 200-205
21. Simonneau G, Gali. N, Rubin LJ et al. Clinical classification of pulmo? nary hypertension. J Am Coll Cardiol 2004; 43: 5S-12S
22. Thabut G, Dauriat G, Stern JB et al. Pulmonary hemodynamics in ad? vanced COPD candidates for lung volume reduction surgery or lung transplantation. Chest 2005; 127: 1531-1536
23. Kessler R, Faller M, Weitzenblum E et al. "Natural history" of pulmonary hypertension in a series of 131 patients with chronic obstructive lung disease. Am J Respir Crit Care Med 2001; 164: 219-224
24. Naeije R. Pulmonary hypertension and right heart failure in COPD. Monaldi Arch Chest Dis 2003; 59: 250-253
25. Kessler R, Faller M, Fourgaut G et al. Predictive Factors of Hospitaliza? tion for Acute Exacerbation in a Series of 64 Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 1999; 159: 158-164
26. Holverda S, Bogaard HJ, Groepenhoff H et al. Cardiopulmonary Exercise Test Characteristics in Patients with Chronic Obstructive Pulmonary Disease and Associated Pulmonary Hypertension. Respiration 2007 Oct 25; [Epub ahead of print]
27. DeMarco FJ Jr, Wynne JW, Block AJ et al. Oxygen desaturation during sleep as a determinant of the "Blue and Bloated" syndrome. Chest 1981; 79: 621-625
28. Sanders MH, Newman AB, Haggerty CL et al. Sleep Heart Health Study. Sleep and Sleep?disordered Breathing in Adults with Predominantly Mild Obstructive Airway Disease. AJRCCM 2003; 167: 7-14
29. McNicholas WT, Calverley PMA, Lee A et al. Tiotropium Sleep Study in COPD Investigators. Long?acting inhaled anticholinergic therapy im? proves sleeping oxygen saturation in COPD. Eur Respir J 2004; 23: 825-831
30. Marin JM, Carrizo SJ, Vicente E et al. Long?term cardiovascular out? comes in men with obstructive sleep apnoea?hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 2005 Mar 19-25; 365 (9464): 1046- 1053
31. Lavie P, Herer P, Lavie L. Mortality risk factors in sleep apnoea: a matched case?control study. J Sleep Res 2007; 16: 128-134
32. Taube C, Lehnigk B, Paasch K et al. Factor analysis of changes in dys? pnea and lung function parameters after bronchodilation in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2000; 162: 216-220
33. Schlecht NF, Schwartzman K, Bourbeau J. Dyspnea as clinical indicator in patients with chronic obstructive pulmonary disease. Chron Respir Dis 2005; 2: 183-191 (Pubitemid 41527260)
34. Vincken W, Noord JA van, Greefhorst APM et al. Dutch/Belgian Tiotropi? um Study Group. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002; 19: 209- 216
35. Casaburi R, Mahler DA, Jones PW et al. A long?term evaluation of once? daily tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19: 217-224
36. O'Donnell DE, Voduc N, Fitzpatrick M et al. Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J 2004; 24: 86-294
37. Hodder RV, White RJ, Menjoge SS et al. Effectiveness of Tiotropium or Salmeterol in COPD patients receiving inhaled steroids. Am J Respir Crit Care Med 2002; 165: A228
38. Jones PW. Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur Respir J 2002; 19: 398-404
39. Calverley PM, Boonsawat W, Cseke Z et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003; 22: 912-919
40. Jones PW, Edin HM, Anderson J. Salmeterol/Fluticasone propionate combination improves health status in COPD patients. Am J Resp Crit Care Med 2002; 165: A111
41. Aaron SD, Vandenheen KL, Fergusson D et al. Canadian Thoracic Socie? ty/Canadian Respiratory Clinical Research Consortium. Tiotropium in combination with placebo, salmeterol, or fluticasone?salmeterol for treatment of chronic obstructive pulmonary disease. Ann Intern Med 2007; 146: 545-555
42. Vijayasaratha K, Stockley RA. Reported and unreported exacerbations of COPD: analysis by diary cards. Chest 2008; 133: 34-41
43. Burge S, Wedzicha JA. COPD exacerbations: definitions and classifica? tions. Eur Respir J 2003; 21: 46s-53s
44. Aaron SD, Fergusson D, Marks GB et al. Canadian Thoracic Society/Ca? nadian Respiratory Clinical Research Consortium. Counting, analyzing and reporting exacerbations of COPD in randomized, controlled trials. Thorax 2008; 63: 122-128
45. Cote CG, Dordelly LJ, Celli BR. Impact of COPD exacerbations on patient? centered outcomes. Chest 2007; 131: 696-704
46. Soler?Cataluæa JJ, Martínez?García MÁ, Snchez PR et al. Severe acute exacerbations and mortality in patients with chronic obstructive pul? monary disease. Thorax 2005; 60: 925-931
47. Niewoehner DE, Lokhnygina Y, Rice K et al. Risk indexes for exacerba? tions and hospitalizations due to COPD. Chest 2007; 131: 20-28
48. Ringbaek T, Seersholm N, Viskum K. Standardised mortality rates in females and males with COPD and asthma. Eur Respir J 2005; 25: 891-895
49. Hansell AL, Walk JA, Soriano JB. What do chronic obstructive pulmo? nary disease patients die from? A multiple cause coding analysis. Eur Respir J 2003; 22: 809-814
50. Ringbaek T, Viskum K. Is there any association between inhaled ipra? tropium and mortality in patients with COPD and asthma? Respir Med 2003; 97: 264-272
51. Zielinski J, MacNee W, Wedzicha J et al. Causes of death in patients with COPD and chronic respiratory failure. Monaldi Arch Chest Dis 1997; 52: 43-47
52. Gudmundsson G, Gislason T, Lindberg E et al. Mortality in COPD pa? tients discharged from hospital: the role of treatment and co?morbi? dity. Respir Res 2006; 16 (7): 109
53. Curkendall SM, Lanes S, de Luise C et al. Chronic obstructive pulmonary disease severity and cardiovascular outcomes. Eur J Epidemiol 2006; 21: 803-813
54. Sin DD, Wu L, Anderson J et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax 2005; 60: 992-997
55. Calverley PMA, Anderson JA, Celli B et al. TORCH investigators. Salme? terol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease. N Engl J Med 2007; 356: 775-789
56. Kesten S, Jara M, Wentworth C et al. Pooled clinical trial analysis of tio? tropium safety. Chest 2006; 13: 1695-1703
57. Celli BR, Cote CG, Marin JM et al. The body?mass index, airflow ob? struction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 1005-1012
58. Casanova C, Cote C, de Torres JP et al. Inspiratory?to?total lung capacity ratio predicts mortality in patients with chronic obstructive pulmo? nary disease. Am J Respir Crit Care Med 2005; 171: 591-597
59. Holguin F, Folch E, Redd SC et al. Comorbidity and mortality in COPD? related hospitalizations in the United States, 1979 to 2001. Chest 2005; 128: 2005-2011
60. Young RP, Hopkins R, Eaton TE. Forced expiratory volume in one second: not just a lung function test but a marker of premature death from all causes. Eur Respir J 2007; 30: 616-622
61. Garcia?Aymerich J, Lange P, Benet M et al. Regular physical activity re? duces hospital admission and mortality in chronic obstructive pulmo? nary disease: a population based cohort study. Thorax 2006; 61: 772- 778
62. Watz H, Waschki B, Boehme C et al. Extrapulmonary effects of chronic obstructive pulmonary disease on physical activity: a cross?sectional study. Am J Respir Crit Care Med 2008; 177: 743-745
63. Wewel AR, Gellermann I, Schwertfeger I et al. Intervention by phone calls raises domiciliary activity and exercise capacity in patients with severe COPD. Respir Med 2008; 102: 20-26
64. Vogelmeier C, Buhl R, Criøe CP et al. Leitlinie der Deutschen Atemwegs? liga und der Deutschen Gesellschaft für Pneumologie und Beat? mungsmedizin zur Diagnostik und Therapie von Patienten mit chro? nisch obstruktiver Bronchitis und Lungenemphysem (COPD). Pneu? mologie 2007; 61: e1-e40
65. Nationale Versorgungsleitlinie COPD NVL Deutscher Ärzte?Verlag, 2007
66. Casaburi R, Kufkafka D, Cooper CB et al. Improvement in exercise tole? rance with the combination of tiotropium and pulmonary rehabilita? tion in patients with COPD. Chest 2005; 127: 809-817
67. Decramer M, Gosselink R, Bartsch P et al. Effect of treatments on the progression of COPD: report of a workshop held in Leuven, 11-12 March 2004. Thorax 2005; 60: 343-349
68. Dhein Y, Birkenmaier A, Otte B et al. Evaluation of a structured educa? tion programme (AFBE) for patients with mild to moderate COPD un? der outpatient conditions. Am J Respir Crit Care Med 2002; 165: A420
69. Tirimanna PR, Den Otter JJ, Van Schayck CP et al. Evaluation of the suitability of weekly peak expiratory flow rate measurements in monitoring annual decline in lung function among patients with asthma and chronic bronchitis. Br J Gen Pract 1996; 46: 15-18
70. Glaab T, Banik N, Rutschmann OT et al. National survey of guideline? compliant COPD management among pneumologists and primary care physicians. COPD 2006; 3: 141-148
71. Nishimura K, Izumi T, Tsukino M et al. Dyspnea is a better predictor of 5?year survival than airway obstruction in patients with COPD. Chest 2002; 121: 1434-1440
72. Burdon JG, Juniper EF, Killian KJ et al. The perception of breathlessness in asthma. Am Rev Respir Dis 1982; 126: 825-828
73. Guyatt GH, Sullivan MJ, Thompson PJ et al. The 6?minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J 1985; 132: 919-923
74. Landbo C, Prescott E, Lange P et al. Prognostic value of nutritional sta? tus in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: 1856-1861 (Pubitemid 30004687)
75. Man SF, Connett JE, Anthonisen NR et al. C?reactive protein and morta? lity in mild to moderate chronic obstructive pulmonary disease. Tho? rax 2006; 61: 849-853
76. Stockley RA. New approaches to the management of COPD. Chest 2000; 117: 58S-62S
77. Vestbo J, Anderson W, Coxson HO et al. ECLIPSE investigators. Eur Re? spir J 2008; 31: 869-873